BofA initiated coverage of Vera Therapeutics (VERA) with a Buy rating and $48 price target The firm sees potential upside in shares coming from its lead drug, atacicept, launching into a multibillion-dollar market, the analyst tells investors. The firm notes that its $3B nominal peak sales forecast for 2037 reflects its view that atacicept could offer a favorable treatment option in multiple autoimmune disorders, pending future clinical data validation.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA: